Accordingly, CD39 and CD39 therapies, that boost local adenosine levels in the brain, are strong therapeutic candidates to treat endothelial dysfunction underlying cerebrovascular diseases. The gene discussed is ENTPD1; the disease is cerebrovascular disorder.